// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Diagnostic ascertainment of axial spondyloarthritis in patients presenting with undiagnosed back pain: what is the impact of mri in rheumatological practice?

R.G. Lambert - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

N/A

Diagnostic delay for rheumatoid arthritis: a systematic review

C.A. Hay - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Diagnostic yield of muscle biopsies performed over a 10 year period

J.M. Weightman - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Differences in clinical manifestations of behcet’s syndrome by gender: cross-sectional analysis in a uk cohort

L. Chadwick - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Behcet disease

N/A

Differential levels of il-7 expression in adventitia of non-ra and ra patients with coronary artery disease

A.N. Burska - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Digital artery volume index: the first objective, automated, non-invasive imaging diagnostic of macrovascular involvement in ssc

G. Lettieri - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Digital technologies to promote self-management in musculoskeletal health: a systematic review

L. Sammut - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Dimethyl fumarate inhibits ube2l3 mediated tlr7 signalling and autoreactive b cell development in sle

D. Mauro - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Dimethyl fumarate

Directly comparing latent functional ability in adolescents with jia using the chaq and haq: an item response theory analysis

S. J. W. Shoop-Worrall - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Disease activity predicts functional impairment and spinal mobility in axial spondyloarthritis

T. Williams - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Axial spondyloarthritis

N/A

Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: moving towards targeted individualised treatment strategy

S.I. Nasef - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Disease, work and personal related factors associated with presenteeism in patients with rheumatoid arthritis: results from the national rheumatoid arthritis society survey (NRAS

S. Verstappen - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Disease-specific autoantibodies associate with remarkably different risk of development of significant lung fibrosis in systemic sclerosis

A. Sari - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Pulmonary arterial hypertension

N/A

Dmard monitoring guidelines and shared prescribing in primary care – is more education required?

G. Choudhury - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Does imaging support the vascular nature of osteoarthritis?

P.G. Conaghan - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Aortic valve calcification

N/A

Does obesity influence ra outcomes ?

P.D. Kiely - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Tocilizumab

Does the presence of ild influence the choice of dmard and biologic therapy in rheumatoid arthritis?

F. Coath - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Methotrexate

Does time matter? a systematic review to assess the relationship between delay in diagnosis and costs in dmard-naÏve ra patients

I. Sahbudin - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Downregulation of microrna may contribute to activation of the interferon signalling pathway in the idiopathic inflammatory myopathies

J.E. Parkes - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

Interferon

Draft classification criteria for the anca associated vasculitides

J.C. Robson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

N/A

Copyright © 2026. QuantiNova All rights reserved